Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5985 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | AZD5985 |
| B | EXPERIMENTAL | placebo |
| Name | Type | Description |
|---|---|---|
| AZD5985 | DRUG | Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits. |
| placebo | DRUG | Oral suspension. |
Inclusion Criteria: * Provision of signed, written and dated informed consent prior to any study specific procedures. * Healthy male subjects aged 18 to 45 years (inclusive). * Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg. * Be non-smoker or ...
AZD5985 is an investigational small molecule being studied in healthy volunteers. It is being evaluated in an exploratory Phase 1 clinical trial to assess its pharmacokinetics, which is how the drug is absorbed, distributed, metabolized, and eliminated by the body. The study is not intended to treat a specific disease.
AZD5985 is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca is listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research on this drug candidate to evaluate its properties in early-stage trials.
AZD5985 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is currently being studied in an early-stage clinical trial to assess its pharmacokinetics in healthy male volunteers. The trial has been completed.
AZD5985 has one completed clinical trial registered under the identifier NCT00799331. The study, titled "Exploratory Study to Assess the Pharmacokinetics of AZD5985," was a Phase 1 trial conducted in Germany with 32 healthy male participants aged 18 years and older. The trial was randomized, double-blind, and controlled.
No alternative names for AZD5985 have been reported. The drug is identified solely by its code name AZD5985 in clinical trial registrations and scientific literature. It is a distinct investigational compound being developed by AstraZeneca.